Radiant Biotherapeutics

We're excited to emerge from #stealth mode today with a $8M #seed #financing. Radiant Biotherapeutics is a revolutionary antibody platform company developing multi-valent, multi-specific therapeutics. Based on foundational IP from the labs of Dr. Jean-Philippe Julien at The Hospital for Sick Children (SickKids) and Dr. Bebhinn Treanor at the University of Toronto, Radiant was created by Amplitude Ventures which also led the seed round along with launch partner, SickKids and additional investors Alexandria Investments, FACIT and TIAP - Toronto Innovation Acceleration Partners. https://lnkd.in/em2GgCxA  

As November comes to a close, we want to shine a light on stomach cancer and those whose lives are affected by this disease. Understanding stomach cancer is key to making a difference. Learn more about its impact and available treatments by visiting the National Cancer Institute (NCI): https://lnkd.in/g9JMM4Kj. #Antibody #November #StomachCancerAwareness #Multabody

Last Friday, the Radiant team gathered for a fun Halloween social, painting their favorite interpretations of jack-o'-lanterns. It was an enjoyable time for everyone! We wish you all a safe and happy Halloween! #Halloween #Radiant #Antibodies #October #Toronto

Wishing a happy Thanksgiving from the Radiant team! Today serves as a time for reflection and gratitude, and we couldn’t be more grateful for the team we have around us and our investors who have supported us through every step of the way. Thank you! Who are you thankful for this season? #antibodies #thanksgiving #canada #multabody #thanksgivingcanada

Today marks four years since Radiant was founded! Built around the foundational science developed at The Hospital for Sick Children (SickKids) in Toronto and the University of Toronto, including work performed at the laboratories of Jean-Philippe Julien, Ph.D., senior scientist at SickKids and associate professor at Temerty Faculty of Medicine, University of Toronto, and Bebhinn Treanor, Ph.D., a professor at the University of Toronto, Radiant Biotherapeutics has emerged as a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. Here’s to another four years of innovation! #antibodies #radiant #amplitude #gates #seriesa #biotech #multabody #anniversary

A recent BioWorld News article highlighted Radiant’s successful $35 million Series A round, which is expected to accelerate our efforts in developing our innovative Multabody™ platform. This funding marks a critical step forward for the company as it drives innovations that could help patients with high unmet medical needs as they deal with life changing disease. Find the article here (paywall): https://lnkd.in/e3uEgC6c #antibodies #radiant #amplitude #gates #seriesa #biotech #bioworld #multabody

October is #BreastCancerAwarenessMonth. This October, Radiant stands with those affected by breast cancer. While our work focuses on developing groundbreaking antibody technologies, we recognize the importance of ongoing research, early detection, and treatment advancements in the fight against this disease. Breast cancer impacts millions of lives, and as we continue to innovate in the field of biotechnology, we are proud to support awareness efforts that bring us closer to a healthier future. #BreastCancerAwareness #Antibodies #BreastCancer #Radiant #Biotech #Canada #Toronto #Cancer #Awareness #Research #multabody

Shining a light on #BloodCancerAwarenessMonth. This September, we mark Blood Cancer Awareness Month to highlight the ongoing battle faced by those living with blood cancers like leukemia and lymphoma. Blood cancers are unique in how they affect the body, often requiring specialized treatments and long-term care. By raising awareness, we can help promote early detection and support the incredible work being done across the medical field. #BloodCancerAwareness #Research #BloodCancer #Blood #Cancer #antibodies #Canada #Toronto #Biotech #Awareness #Radiant #multabody

Radiant Therapeutics is thrilled to announce the closing of its $35 million Series A financing. This is an important step forward for Radiant. We’ll be adding key members to our team, and accelerating the advance of our lead clinical candidate, 4-1BB, towards clinical trials. I want to personally thank our supportive investors at the Bill & Melinda Gates Foundation and Amplitude Ventures, who are co-leads of the round. Also the investors at BDC Capital, abrdn., who are new to Radiant; and existing investors at FACIT, Alexandria Venture Investments and TIAP - Toronto Innovation Acceleration Partners.   All of our investors see the potential of the Multabody™ platform, which creates a new class of biologics with an unprecedented combination of multivalency, which results in greater avidity or powerful grip on targets and multi-specificity. Multabodies do things that other existing and developmental antibody treatments can’t do, and that’s why we’re so excited about bringing this powerful new tool to the fight against difficult, heterogeneous diseases.   Finally, the Radiant team has brought extraordinary determination and passion to our mission. This is a day to celebrate before we dig in to the hard work ahead of us as we further develop the Multabody platform. Please read our full press release here: www.radiantbio.com. #Radiant #Multabody #Antibodies #Bio #Biotherapeutics #LifeSciences #Cancer #DrugDiscovery #SeriesA #Financing

Radiant Biotherapeutics CEO Art Fratamico will be presenting at the upcoming Life Sciences Future Conference hosted by Life Sciences Pennsylvania. Art will share details about Radiant’s innovative Multabody™ platform, which produces innovative biologics for conditions that don’t respond to traditional antibody treatments, such as cancer, autoimmune and infectious diseases. Learn more about this event here > > https://bit.ly/47wtA7T #LifeSciences #Biotherapeutics #Conference #Radiant #Bio #Antibodies #Cancer #DrugDiscovery